Loading...
VIMIAN logo

Vimian Group AB (publ)OM:VIMIAN 주식 보고서

시가총액 SEK 15.9b
주가
SEK 30.10
SEK 33.82
11.0% 저평가 내재 할인율
1Y-21.9%
7D5.8%
포트폴리오 가치
​
보기

Vimian Group AB (publ)

OM:VIMIAN 주식 리포트

시가총액: SEK 15.9b

Vimian Group (VIMIAN) 주식 개요

비미안 그룹은 전 세계에서 동물 건강 사업을 영위하는 기업입니다. 자세히 보기

VIMIAN 펀더멘털 분석
스노우플레이크 점수
가치 평가3/6
미래 성장4/6
과거 실적4/6
재무 건전성4/6
배당0/6

강점

공정 가치 추정치보다 낮은 20.8% 에서 거래

수익은 매년 27.58% 증가할 것으로 예상됩니다.

지난 1년간 수익이 90.7% 증가했습니다.

위험 분석

우리의 위험 점검에서 VIMIAN에 대한 위험이 감지되지 않았습니다.

VIMIAN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives

Vimian Group AB (publ) 경쟁사

가격 이력 및 성과

Vimian Group 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가SEK 30.10
52주 최고가SEK 46.00
52주 최저가SEK 24.18
베타1.18
1개월 변동4.95%
3개월 변동13.07%
1년 변동-21.86%
3년 변동-18.65%
5년 변동n/a
IPO 이후 변동-62.79%

최근 뉴스 및 업데이트

VIMIAN: Higher Discount Rate Will Constrain Future Upside Potential

Analysts have trimmed their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated views on discount rates, growth and profitability assumptions. Analyst Commentary Bearish analysts are signaling a more cautious stance on Vimian Group, with the latest move being a reduction in the price target to SEK 25 from SEK 27.

VIMIAN: Margin Execution And New Bylaws Will Support Future Upside Potential

Analysts have reduced their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on margins and valuation multiples that result in a slightly adjusted fair value model. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with the updated SEK 25 price target reflecting revised assumptions on margins and valuation multiples rather than a shift in rating.

Recent updates

VIMIAN: Higher Discount Rate Will Constrain Future Upside Potential

Analysts have trimmed their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated views on discount rates, growth and profitability assumptions. Analyst Commentary Bearish analysts are signaling a more cautious stance on Vimian Group, with the latest move being a reduction in the price target to SEK 25 from SEK 27.

VIMIAN: Margin Execution And New Bylaws Will Support Future Upside Potential

Analysts have reduced their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on margins and valuation multiples that result in a slightly adjusted fair value model. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with the updated SEK 25 price target reflecting revised assumptions on margins and valuation multiples rather than a shift in rating.

VIMIAN: Lower Price Outlook And Execution Risks Will Shape Fair Value Balance

Analysts have trimmed their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on growth, margins and valuation multiples that align the target more closely with recent research views. Analyst Commentary Recent research reflects a cautious tone around Vimian Group, with the latest move being a trim in the price target to SEK 25 from SEK 27.

VIMIAN: Reduced Price Outlook And Execution Risks Will Shape Fairly Balanced Prospects

Analysts have lowered their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts have trimmed their fair value assumptions for Vimian Group, as seen in the reduced price target to SEK 25 from SEK 27.

VIMIAN: Reset Expectations Will Highlight Execution Under New CEO Appointment

Analysts have trimmed their fair value estimate and price target on Vimian Group to SEK 27 from SEK 37, reflecting updated assumptions around slightly higher growth, a lower profit margin profile and a higher expected P/E multiple, which together point to a more cautious risk return trade off. Analyst Commentary Bullish analysts looking at Vimian Group are focusing less on the headline downgrade and more on what the revised SEK 27 target implies for execution, valuation and growth expectations from here.

Vimian Group AB (publ) (STO:VIMIAN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 16
Vimian Group AB (publ) (STO:VIMIAN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Is Vimian Group (STO:VIMIAN) Using Too Much Debt?

Feb 05
Is Vimian Group (STO:VIMIAN) Using Too Much Debt?

VIMIAN: Future Leadership Change Will Support Execution Upside Despite Sector Downgrade

Narrative update Analysts have trimmed their price expectations for Vimian Group, with the updated fair value estimate easing from SEK 36.92 to SEK 33.76, as some now see lower future P/E assumptions and have adopted more cautious views similar to the recent SEK 27 price target cut in Street research. Analyst Commentary Recent research updates on Vimian Group have taken a more cautious tone, with the shift to an Underweight rating and a price target of SEK 27, down from SEK 37.

VIMIAN: Rebased Expectations Will Spotlight Execution Under New Leadership Transition Narrative

Analysts have reduced their fair value estimate for Vimian Group to SEK 41.36 from SEK 41.97, citing slightly higher discount rate assumptions and updated sector views. This follows a recent cut in the Street price target to SEK 27 from SEK 37.

VIMIAN: Rebased Expectations Will Highlight Execution On M&A-Led Expansion Narrative

Analysts have lowered their fair value estimate for Vimian Group from SEK 51.65 to SEK 41.97, citing more cautious assumptions on revenue growth and valuation multiples in line with recent price target cuts, including the move to SEK 27 from SEK 37 in Barclays' 2026 industry outlook. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with fair value and price targets recalibrated to reflect updated assumptions on revenue growth and sector valuation.

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Jan 08
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

VIMIAN: Downgrade And New CEO Will Shape Medium Term Risk Outlook

Analysts have lowered their price target on Vimian Group from approximately SEK 37 to around SEK 27. This reflects more cautious assumptions on growth, profitability, and valuation multiples in line with a more conservative sector outlook for 2026.

VIMIAN: Future Leadership Will Drive Cash Flow Execution Upside Despite Sector Downgrade

Analysts have trimmed their price target on Vimian Group by SEK 10 to SEK 27. This reflects slightly higher discount rate assumptions and more conservative long term valuation multiples for the sector.

VIMIAN: Future Leadership and Expanded Acquisitions Will Drive Market Resilience

Narrative Update on Vimian Group Analysts have lowered Vimian Group's fair value estimate from SEK 38.90 to SEK 36.97. This revision is attributed to reduced revenue growth expectations, a higher discount rate, and a more cautious industry outlook reflected in recent research.

Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 40% Above Its Share Price

Sep 10
Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 40% Above Its Share Price

Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare

Ongoing execution challenges in MedTech, anticipated organic growth slowing to 5% in 2025, and required recovery in orthopedics have led analysts to adopt a more cautious outlook and maintain Vimian Group's price target at SEK38.90. Analyst Commentary Ongoing execution challenges in the MedTech segment are impacting overall group momentum.

Vimian Group AB (publ) (STO:VIMIAN) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

Aug 14
Vimian Group AB (publ) (STO:VIMIAN) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

If EPS Growth Is Important To You, Vimian Group (STO:VIMIAN) Presents An Opportunity

Jun 17
If EPS Growth Is Important To You, Vimian Group (STO:VIMIAN) Presents An Opportunity

Estimating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)

Jun 02
Estimating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)

Getting In Cheap On Vimian Group AB (publ) (STO:VIMIAN) Is Unlikely

May 15
Getting In Cheap On Vimian Group AB (publ) (STO:VIMIAN) Is Unlikely

Is Vimian Group (STO:VIMIAN) A Risky Investment?

Mar 05
Is Vimian Group (STO:VIMIAN) A Risky Investment?

Vimian Group's (STO:VIMIAN) Earnings Are Weaker Than They Seem

Feb 21
Vimian Group's (STO:VIMIAN) Earnings Are Weaker Than They Seem

A Look At The Fair Value Of Vimian Group AB (publ) (STO:VIMIAN)

Feb 14
A Look At The Fair Value Of Vimian Group AB (publ) (STO:VIMIAN)
User avatar

iM3 Acquisition Will Expand Presence In Veterinary Dental Space

Expansion in Specialty Pharma and strategic focus on cash generation are expected to drive organic growth, enhancing revenue and margins.

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Dec 16
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%

Aug 31
Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%

Is Vimian Group (STO:VIMIAN) A Risky Investment?

Aug 17
Is Vimian Group (STO:VIMIAN) A Risky Investment?

Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 18
Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate

Apr 09
Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate

Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital

Feb 13
Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital

Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues

Jan 08
Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues

Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching

Dec 03
Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching

There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital

Nov 01
There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital

주주 수익률

VIMIANSE Medical EquipmentSE 시장
7D5.8%-2.5%-1.9%
1Y-21.9%-9.8%11.0%

수익률 대 산업: VIMIAN은 지난 1년 동안 -9.8%의 수익을 기록한 Swedish Medical Equipment 산업보다 저조한 성과를 냈습니다.

수익률 대 시장: VIMIAN은 지난 1년 동안 11%를 기록한 Swedish 시장보다 저조한 성과를 냈습니다.

주가 변동성

Is VIMIAN's price volatile compared to industry and market?
VIMIAN volatility
VIMIAN Average Weekly Movement5.8%
Medical Equipment Industry Average Movement7.8%
Market Average Movement6.6%
10% most volatile stocks in SE Market13.0%
10% least volatile stocks in SE Market3.8%

안정적인 주가: VIMIAN는 지난 3개월 동안 Swedish 시장에 비해 주가 변동성이 크지 않았습니다.

시간에 따른 변동성: VIMIAN의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.

회사 소개

설립직원 수CEO웹사이트
20201,033Alireza Tajbakhshvimian.com

비미안 그룹 AB(publ)는 전 세계적으로 동물 건강 사업에 종사하고 있습니다. 특수 제약, 의료 기술, 진단 및 수의학 서비스 부문을 통해 사업을 운영하고 있습니다. 이 회사는 반려동물의 만성 질환 예방 및 치료를 위한 독점 진단, 처방 및 비처방 치료제를 넥스트뮨 브랜드 이름으로 제공하고, 가축 및 반려동물 건강 시장에 초점을 맞춘 수의학 관련 응용 분야에서 실험실에서 사용하는 분자 및 면역 진단 솔루션을 인디컬 바이오사이언스 브랜드 이름으로 제공합니다.

Vimian Group AB (publ) 기초 지표 요약

Vimian Group의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
VIMIAN 기초 통계
시가총액SEK 15.93b
순이익 (TTM)SEK 397.92m
매출 (TTM)SEK 4.69b
40.0x
주가수익비율(P/E)
3.4x
주가매출비율(P/S)

VIMIAN는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
VIMIAN 손익계산서 (TTM)
매출€433.60m
매출원가€134.40m
총이익€299.20m
기타 비용€262.40m
순이익€36.80m

최근 보고된 실적

Mar 31, 2026

다음 실적 발표일

Jul 17, 2026

주당순이익(EPS)0.07
총이익률69.00%
순이익률8.49%
부채/자본 비율31.5%

VIMIAN의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/03 17:02
종가2026/04/30 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Vimian Group AB (publ)는 10명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
null nullABG Sundal Collier
Jonathon UnwinBarclays
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB